Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

Trial Details

NCT ID
NCT05806931
Phase
PHASE2
Sponsor
Rutgers, The State University of New Jersey
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • TAS-102, oxaliplatin, irinotecan with bevacizumab
Locations (sample)
  • Elizabeth, New Jersey, United States|40.66399,-74.2107
  • Jersey City, New Jersey, United States|40.72816,-74.07764
  • Lakewood, New Jersey, United States|40.09789,-74.21764
  • Livingston, New Jersey, United States|40.79593,-74.31487
  • Long Branch, New Jersey, United States|40.30428,-73.99236

Key Eligibility Criteria

  • Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan, oxalip…
  • Participants who had received adjuvant chemotherapy and had recurrence during or within six months of completion of the adjuvant chemotherapy will …
  • Progression of disease must be documented on the most recent scan.
  • Presence of measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →